Market Cap ₹199 Cr.
Stock P/E 20.0
P/B 2.6
Current Price ₹111.8
Book Value ₹ 43.6
Face Value 10
52W High ₹189
Dividend Yield 0%
52W Low ₹ 102.6
QMS Medical Allied Services Ltd is a reputable company that specializes in providing comprehensive medical and allied services. With a commitment to excellence, they offer a wide range of healthcare solutions to meet the needs of patients, medical professionals, and healthcare institutions. Their services encompass medical staffing, healthcare consulting, medical equipment supply, and facility management. QMS Medical Allied Services Ltd prides itself on its highly skilled and experienced team of medical professionals, administrators, and support staff who work diligently to ensure the delivery of top-quality healthcare services. They maintain stringent quality control measures to uphold the highest standards of patient care, regulatory compliance, and customer satisfaction. The company places a strong emphasis on continuous improvement, staying up-to-date with the latest advancements in medical technology and best practices. QMS Medical Allied Services Ltd is recognized for its reliability, efficiency, and customer-centric approach, making it a trusted partner in the healthcare industry. Whether it's providing staffing solutions for medical facilities or delivering specialized healthcare consulting services, the company is dedicated to improving healthcare outcomes and fostering a healthier community.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|---|
Net Sales | 25 | 27 | 21 | 26 | 29 | 35 |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 |
Total Income | 25 | 28 | 21 | 26 | 29 | 35 |
Total Expenditure | 23 | 25 | 17 | 21 | 24 | 30 |
Operating Profit | 2 | 3 | 4 | 5 | 5 | 5 |
Interest | 1 | 1 | 0 | 1 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 1 | 1 | 1 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 1 | 2 | 3 | 3 | 3 | 3 |
Provision for Tax | 0 | 1 | 1 | 1 | 1 | 1 |
Profit After Tax | 1 | 2 | 3 | 2 | 3 | 2 |
Adjustments | 0 | -0 | 0 | 0 | -0 | 0 |
Profit After Adjustments | 1 | 2 | 3 | 2 | 3 | 2 |
Adjusted Earnings Per Share | 0.4 | 1.1 | 1.4 | 1.4 | 1.4 | 1.4 |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|---|
Net Sales | 52 | 73 | 122 | 146 | 104 | 111 |
Other Income | 0 | 0 | 0 | 1 | 1 | 0 |
Total Income | 52 | 73 | 122 | 148 | 105 | 111 |
Total Expenditure | 47 | 63 | 105 | 130 | 93 | 92 |
Operating Profit | 5 | 10 | 17 | 18 | 12 | 19 |
Interest | 0 | 1 | 1 | 2 | 2 | 3 |
Depreciation | 0 | 0 | 1 | 1 | 1 | 3 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 4 | 9 | 15 | 14 | 9 | 12 |
Provision for Tax | 1 | 2 | 4 | 4 | 2 | 4 |
Profit After Tax | 3 | 6 | 11 | 11 | 6 | 10 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 3 | 6 | 11 | 11 | 6 | 10 |
Adjusted Earnings Per Share | 2 | 4.2 | 7.3 | 7.1 | 3.6 | 5.6 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | -29% | 13% | 0% | 0% |
Operating Profit CAGR | -33% | 6% | 0% | 0% |
PAT CAGR | -45% | 0% | 0% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | -26% | NA% | NA% | NA% |
ROE Average | 13% | 43% | 66% | 66% |
ROCE Average | 14% | 33% | 45% | 45% |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Shareholder's Funds | 3 | 9 | 20 | 31 | 70 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 |
Borrowings | 0 | 0 | 1 | 2 | 1 |
Other Non-Current Liabilities | -0 | -0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 24 | 39 | 52 | 46 |
Total Liabilities | 18 | 33 | 60 | 85 | 118 |
Fixed Assets | 0 | 3 | 10 | 8 | 25 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 5 |
Total Current Assets | 18 | 30 | 50 | 77 | 88 |
Total Assets | 18 | 33 | 60 | 85 | 118 |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 0 | 0 | 1 | 1 | 2 |
Cash Flow from Operating Activities | -4 | -3 | 2 | -2 | -8 |
Cash Flow from Investing Activities | -0 | -4 | -8 | 2 | -25 |
Cash Flow from Financing Activities | 5 | 7 | 7 | 0 | 32 |
Net Cash Inflow / Outflow | 0 | 1 | 1 | 1 | -1 |
Closing Cash & Cash Equivalent | 0 | 1 | 1 | 2 | 1 |
# | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Earnings Per Share (Rs) | 2.02 | 4.22 | 7.25 | 7.1 | 3.57 |
CEPS(Rs) | 2.04 | 4.46 | 7.74 | 7.87 | 4.17 |
DPS(Rs) | 0 | 0 | 0 | 0 | 0.5 |
Book NAV/Share(Rs) | 2.03 | 6.25 | 13.5 | 20.62 | 39.44 |
Core EBITDA Margin(%) | 8.96 | 13.2 | 13.93 | 11.37 | 10.89 |
EBIT Margin(%) | 8.92 | 12.76 | 13.37 | 11.55 | 10.57 |
Pre Tax Margin(%) | 8.43 | 11.99 | 12.21 | 9.88 | 8.37 |
PAT Margin (%) | 5.85 | 8.74 | 8.95 | 7.3 | 6.13 |
Cash Profit Margin (%) | 5.92 | 9.23 | 9.55 | 8.1 | 7.16 |
ROA(%) | 16.97 | 24.76 | 23.27 | 14.7 | 6.27 |
ROE(%) | 99.46 | 102.03 | 73.44 | 41.62 | 12.58 |
ROCE(%) | 60.89 | 64.85 | 53.55 | 32.83 | 13.83 |
Receivable days | 56.39 | 48.25 | 51.14 | 81.1 | 142.24 |
Inventory Days | 62.98 | 61.84 | 53.84 | 55.58 | 95.04 |
Payable days | 79.4 | 69.29 | 59.68 | 58.07 | 84.95 |
PER(x) | 0 | 0 | 0 | 0 | 36.58 |
Price/Book(x) | 0 | 0 | 0 | 0 | 3.31 |
Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.38 |
EV/Net Sales(x) | 0.09 | 0.19 | 0.18 | 0.23 | 2.46 |
EV/Core EBITDA(x) | 0.95 | 1.45 | 1.29 | 1.86 | 21.26 |
Net Sales Growth(%) | 0 | 40.17 | 67.77 | 19.9 | -28.89 |
EBIT Growth(%) | 0 | 100.39 | 75.82 | 3.55 | -34.93 |
PAT Growth(%) | 0 | 109.43 | 71.72 | -2.11 | -40.32 |
EPS Growth(%) | 0 | 109.43 | 71.72 | -2.11 | -49.68 |
Debt/Equity(x) | 1.49 | 1.23 | 0.96 | 1.03 | 0.36 |
Current Ratio(x) | 1.2 | 1.25 | 1.28 | 1.48 | 1.9 |
Quick Ratio(x) | 0.63 | 0.6 | 0.76 | 1.01 | 1.25 |
Interest Cover(x) | 18.06 | 16.6 | 11.58 | 6.93 | 4.81 |
Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.11 |
# | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 |
---|---|---|---|---|
Promoter | 73.67 | 73.67 | 73.67 | 73.67 |
FII | 0.71 | 1.21 | 1.02 | 0.01 |
DII | 0 | 0 | 0 | 0 |
Public | 25.63 | 25.12 | 25.31 | 26.33 |
Others | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 |
# | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 |
---|---|---|---|---|
Promoter | 1.31 | 1.31 | 1.31 | 1.31 |
FII | 0.01 | 0.02 | 0.02 | 0 |
DII | 0 | 0 | 0 | 0 |
Public | 0.46 | 0.45 | 0.45 | 0.47 |
Others | 0 | 0 | 0 | 0 |
Total | 1.79 | 1.79 | 1.79 | 1.79 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About